SGLT-2 Inhibitors: The Best Bet Among New T2D Drugs?

Sodium-glucose cotransporter 2 (SGLT-2) inhibitors came out on top in a large meta-analysis of clinical trials that compared the newer classes of diabetes drugs head-to-head in terms of mortality, cardiovascular, and safety endpoints.

Source: SGLT-2 Inhibitors: The Best Bet Among New T2D Drugs?